Pulmonary Embolism in the ER

  • Carlos Jerjes-SánchezEmail author
  • Jose Gildardo Paredes-Vázquez
  • David Rodríguez
  • Mauricio Vázquez Guajardo
  • Raul del Toro-Mijares


Pulmonary embolism is the third most common cause of cardiovascular mortality after myocardial infarction and stroke. Atherosclerosis risk factors are the rule in outpatients with apparent unprovoked pulmonary embolism. Acute or chronic infections triggering immunothrombosis and inflammation are possibly the main mechanism in older unprovoked pulmonary embolism outpatients. Pulmonary embolism is frequently seen in unexplained acute exacerbation of chronic pulmonary obstructive disease, patients with community-acquired pneumonia, unexplained worsening of dyspnea, chronic atrial fibrillation patients, and in elderly patients with syncope, with or without an alternative explanation. A fast-track approach is the cornerstone of the initial workup. Pulmonary vascular obstruction of >25% is associated with pulmonary hypertension, right ventricular dysfunction, and clinical instability. Normal blood pressure cannot exclude impending clinical instability and in-hospital poor outcome in submassive pulmonary embolism. We suggest a multimodal approach to identify right ventricular dysfunction. A normal electrocardiogram or chest X-ray is unlikely in submassive or massive pulmonary embolism. Clinical condition, right ventricular dysfunction, and risk for major bleeding drive treatment choices. Patients who receive heparin until after hospital admission have increased mortality. Parenteral/oral anticoagulation and systemic thrombolysis are the foundation of treatment in low-risk and massive pulmonary embolism, respectively. A weight-adjusted unfractionated heparin regimen is recommended in those with impending unstable submassive pulmonary embolism and as adjunctive treatment in massive pulmonary embolism. Tenecteplase or alteplase is an option in <65 years and half-dose alteplase in >65 years pulmonary embolism patients. Also, low-dose alteplase is safe and effective in catheter- or ultrasound-directed thrombolysis.


Pulmonary embolism Thrombolysis Oral anticoagulation 


  1. 1.
    Vazquez-Garza E, Jerjes-Sanchez C, Navarrete A, Joya-Harrison J, Rodriguez D. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolysis. 2017;44:377–85.CrossRefGoogle Scholar
  2. 2.
    Miano TA, Cuker A, Christie JD, Martin N, Smith B, Makley AT, et al. Comparative effectiveness of Enoxaparin vs Dalteparin for Thromboprophylaxis after traumatic injury. Chest. 2018;153:133–42.CrossRefGoogle Scholar
  3. 3.
    Jaber WA, Fong PP, Weisz G, Lattouf O, Jenkins J, Rosenfield K, et al. Acute pulmonary embolism. J Am Coll Cardiol. 2016;67:991–1002.CrossRefGoogle Scholar
  4. 4.
    Frank Peacock W, Coleman CI, Diercks DB, Francis S, Kabrhel C, Keay C, et al. Emergency department discharge of pulmonary embolus patients. Acad Emerg Med. 2018;25:995–1003.CrossRefGoogle Scholar
  5. 5.
    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585–93.CrossRefGoogle Scholar
  6. 6.
    2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014;35:3033–73.Google Scholar
  7. 7.
    Jerjes-Sanchez C, Fajardo PG. Patients for thrombolysis. In: Jerjes-Sanchez C, editor. Thrombolysis in pulmonary embolism. Cham: Springer International Publishing; 2015. p. 107–30.CrossRefGoogle Scholar
  8. 8.
    Prandoni P, Lensing AWA, Prins MH, Ciammaichella M, Perlati M, Mumoli N, et al. Prevalence of pulmonary embolism among patients hospitalized for syncope. N Engl J Med. 2016;375:1524–31.CrossRefGoogle Scholar
  9. 9.
    Aleva FE, Voets LWLM, Simons SO, de Mast Q, van der Ven AJAM, Heijdra YF. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD. Chest. 2017;151:544–54.CrossRefGoogle Scholar
  10. 10.
    Zhang Y, Zhou Q, Zou Y, Song X, Xie S, Tan M, et al. Risk factors for pulmonary embolism in patients preliminarily diagnosed with community-acquired pneumonia: a prospective cohort study. J Thromb Thrombolysis. 2016;41:619–27.CrossRefGoogle Scholar
  11. 11.
    Hald EM, Rinde LB, Løchen M, Mathiesen EB, Wilsgaard T, Njølstad I, et al. Atrial fibrillation and cause-specific risks of pulmonary embolism and ischemic stroke. J Am Heart Assoc. 2018;7(3):e006502. Scholar
  12. 12.
    Doyen D, Castellani M, Moceri P, Chiche O, Lazdunski R, Bertora D, et al. Patent foramen Ovale and stroke in intermediate-risk pulmonary embolism. Chest. 2014;146:967–73.CrossRefGoogle Scholar
  13. 13.
    Trevino AR, Perez L, Jerjes-Sanchez C, Rodriguez D, Panneflek J, Ortiz-Ledesma C, et al. Factor Xa inhibition and sPESI failure in intermediate-high-risk pulmonary embolism. Am J Emerg Med. 2018;36:1925.e3–4.CrossRefGoogle Scholar
  14. 14.
    Hellenkamp K, Kaeberich A, Schwung J, Konstantinides S, Lankeit M. Risk stratification of normotensive pulmonary embolism based on the sPESI — does it work for all patients? Int J Cardiol. 2015;197:162–3.CrossRefGoogle Scholar
  15. 15.
    Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123:1788–830.CrossRefGoogle Scholar
  16. 16.
    Agnelli G, Becattini C. Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach. Eur Respir J. 2015;45:1142–9.CrossRefGoogle Scholar
  17. 17.
    Jerjes-Sanchez C. Guías para Anticoagulación y Trombolisis del Tromboembolismo Venoso, Infarto con Elevación del ST, Cardioembolismo Cerebral y del Infarto Cerebral Agudo. Arch Cardiol Mex. 2017;87:1–66.Google Scholar
  18. 18.
    Keller K, Beule J, Balzer JO, Dippold W. Blood pressure for outcome prediction and risk stratification in acute pulmonary embolism. Am J Emerg Med. 2015;33:1617–21.CrossRefGoogle Scholar
  19. 19.
    Qaddoura A, Digby GC, Kabali C, Kukla P, Zhan Z-Q, Baranchuk AM. The value of electrocardiography in prognosticating clinical deterioration and mortality in acute pulmonary embolism: a systematic review and meta-analysis. Clin Cardiol. 2017;40:814–24.CrossRefGoogle Scholar
  20. 20.
    Jerjes-Sanchez C, Ramirez-Rivera A, Ibarra-Perez C. Pulmonary embolism and bradycardia. Intercont Cardiol. 1996;5:27–9.Google Scholar
  21. 21.
    Quintanilla J, Jerjes-Sanchez C, Perez L, Valdes F, Jimenez V, Trevino AR, et al. Intermediate- to high-risk pulmonary embolism with normal B-type natriuretic peptide. Am J Emerg Med. 2016;34:2463.e1–3.CrossRefGoogle Scholar
  22. 22.
    Lankeit M, Jiménez D, Kostrubiec M, Dellas C, Hasenfuss G, Pruszczyk P, et al. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation. 2011;124:2716–24.CrossRefGoogle Scholar
  23. 23.
    Quiroz R, Kucher N, Zou KH, Kipfmueller F, Costello P, Goldhaber SZ, et al. Clinical validity of a negative computed tomography scan in patients with suspected pulmonary embolism: a systematic review. JAMA. 2005;293:2012.CrossRefGoogle Scholar
  24. 24.
    Smith CE, Piamjariyakul U, Wick JA, Spertus JA, Russell C, Dalton KM, et al. Multidisciplinary group clinic appointments: the self-management and Care of Heart Failure (SMAC-HF) trial. Circ Heart Fail. 2014;7:888–94.CrossRefGoogle Scholar
  25. 25.
    Abraham P, Arroyo DA, Giraud R, Bounameaux H, Bendjelid K. Understanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and high-risk pulmonary embolism: a hypothesis paper. Open Heart. 2018;5:e000735.CrossRefGoogle Scholar
  26. 26.
    Jerjes-Sánchez C, Villarreal-Umaña S, Ramírez-Rivera A, Garcia-Sosa A, Miguel-Canseco L, Archondo T, et al. Improving adjunctive treatment in pulmonary embolism and fibrinolytic therapy. The role of enoxaparin and weight-adjusted unfractionated heparin. J Thromb Thrombolysis. 2009;27:154–62.CrossRefGoogle Scholar
  27. 27.
    Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370:1402–11.CrossRefGoogle Scholar
  28. 28.
    Corrigan D, Prucnal C, Kabrhel C. Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients. Clin Exp Emerg Med. 2016;3:117–25.CrossRefGoogle Scholar
  29. 29.
    Tapson VF, Sterling K, Jones N, Elder M, Tripathy U, Brower J, et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism. JACC Cardiovasc Interv. 2018;11:1401–10.CrossRefGoogle Scholar
  30. 30.
    Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O’Neil BJ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department. J Am Coll Cardiol. 2011;57:700–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Instituto de Cardiología y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnológico de MonterreySan Pedro Garza GarcíaMéxico
  2. 2.Centro de Investigación Biomédica del Hospital Zambrano Hellion, TecSalud, Escuela de Medicina, Tecnológico de MonterreySan Pedro Garza GarcíaMéxico
  3. 3.Escuela de Medicina y Ciencias de la Salud, Tecnológico de MonterreyMonterreyMéxico

Personalised recommendations